The Urokinase Receptor: Involvement in Cell Surface Proteolysis and Cancer Invasion

Annals of the New York Academy of Sciences

Volumn 667, Issue 1, 1992, Pages 13-31

  ELLIS, VINCENT ^a   PYKE, CHARLES ^a   ERIKSEN, JENS ^a   SOLBERG, HELENE ^a   DANØ, KELD ^a  

^a FINSEN LABORATORY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CELL SURFACE RECEPTOR; PLASMIN; PLASMINOGEN; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR; PROTEINASE; PROTEINASE INHIBITOR; UROKINASE;

ANIMAL TISSUE; CANCER INVASION; CELL INTERACTION; CELL INVASION; CELL SURFACE; CELLULAR DISTRIBUTION; CONFERENCE PAPER; CONTROLLED STUDY; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MOLECULAR CLONING; MOUSE; NONHUMAN; PERIPHERAL LYMPHOCYTE; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; RECEPTOR BINDING; REGULATORY MECHANISM; STROMA; TISSUE INJURY; TUMOR; TUMOR CELL;

ANIMAL; CELL MEMBRANE; ENDOPEPTIDASES; HUMAN; LEUKOCYTES; NEOPLASM INVASIVENESS; NEOPLASMS; PLASMIN; PLASMINOGEN; RECEPTORS, CELL SURFACE; URINARY PLASMINOGEN ACTIVATOR;

ANIMALIA;

EID: 0027076170     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1992.tb51591.x     Document Type: Article

References (87)

1. Plasminogen activators, tissue degradation, and cancer
2. Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation
3. Proteolytic degradation of extracellular matrix in tumor invasion
4. Cathepsin D in breast cancer: From molecular and cellular biology to clinical applications
5. Urokinase‐type plasminogen activator (u‐PA) antigen is a predictor of early relapse in breast cancer
6. Urokinase‐plasminogen activator, a new and independent prognostic marker in breast cancer
7. Role of the urokinase receptor in facacilitating extracellular matrix invasion by cultured colon cancer
8. Fibrinolysis associated with oncogenic transformation: Partial purification and characterization of the cell factor‐a plasminogen activator
9. Tumor invasion through the human amniotic membrane: Requirement for a proteinase cascade
10. Mouse L cells expressing human prourokinase‐type plasminogen activator: Effects on extracellular matrix degradation and invasion
11. Bimodal relationship between invasion of the amniotic membrane and plasminogen activator activity
12. In vivo invasion of modified chorioallantoic membrane by tumor cells: The role of cell surface‐bound urokinase
13. Complementation between urokinase‐producing and receptor‐producing cells in extracellular matrix degradation
14. Plasminogen activator dependent pathways in the dissemination of human tumor cells in the chick embryo
15. Inhibition of urokinase‐type plasminogen activator by antibodies‐The effect on dissemination of a human tumor in the nude mouse
16. Metastatic behavior of human melanoma cell lines in nude mice correlates with urokinase‐type plasminogcn activator, in type‐1 inhibitor, and urokinase‐mediated matrix degradation
17. Molecular organization and function of the complement system
18. Cofactor proteins in the assembly and expression of blood clotting enzyme complexes
19. A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase
20. Differentiation‐enhanced binding of the amino‐terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes
21. Cryptic urokinase binding sites on human foreskin fibroblasts
22. The plasminogen system and cell surfaces: Evidence for plasminogen and urokinase receptors on the same cell type
23. A 55,000‐60,000 Mr receptor protein fix urokinase‐type plasminogen activator. Identification in human tumor cell lines and partial purification
24. Association of a protease (plasminogen activator) with a specific membrane fraction isolated from transformed cells
25. Immunocytochemical localization of urokinase‐type plasminogen activator in Lewis lung carcinoma
26. Binding of single‐chain prourokinase to the urokinase receptor of human U937 cells
27. Surface receptors for urokinase plasminogen activator
28. The receptor‐binding sequence of urokinase
29. 2‐terminal amino acid sequence and glycosylation variants
30. Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis
31. Protein structure and membrane anchorage of the cellular receptor for urokinase‐type plasminogen activator
32. The ligand‐binding domain of the cell surface receptor for urokinase‐type plasminogen activator
33. Cellular receptor for urokiriase plasminogen activator‐ Carboxyl‐terminal processing and membrane anchoring by glycosyl‐phosphatidylinositol
34. The glycosyl‐phosphatidylinositol anchor of membrane proteins
35. Receptor‐mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI‐1
36. Characterization of the cellular binding site for the urokinase‐type plasminogen activator
37. Transformation‐dependent activation of urokinase‐type plasminogen activator by a plasmin‐independent mechanism‐Involvement of cell surface membranes
38. The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes
39. Identification and characterization of the murine cell surface receptor for urokinase type plasminogen activator
40. Two alternatively spliced mouse urokinase receptor mRNA's with different histological localization in the gastrointestinal tract
41. Distinct localizations of urokinase‐type plasminogen activator and its type 1 inhibitor under cultured human fibroblasts and sarcoma cells
42. Ultrastructural localization of plasma membrane‐associated urokinase‐type plasminogen activator at focal contacts
43. Linkage of extracellular plasminogen activator to the fibroblast cystoskeleton: Colocalization of cell surface urokinase with vinculin
44. Stimulation of cell surface plasminogen activation by heparin and related polyionic substances
45. Purification of zymogen to plasminogen activator from human glioblastoma cells by affinity chromatography with monoclonal antibody
46. Plasminogen activation by single‐chain urokinase in functional isolation
47. One‐chain urokinase‐type plasminogen activator from human sarcoma cells is a proenzyme with little or no intrinsic activity
48. Plasminogen activation initiated by single‐chain urokinase‐type plasminogen activator. Potentiation by U937 monocytes
49. 2‐terminal domain of the urokinase receptor
50. Cellular modulation of plasminogen activation initiated by single‐chain urokinase‐type plasminogen activator
51. Activation of prourokinase and plasminogen on human sarcoma cells: A proteolytic system with surface‐bound reactants
52. Plasminogen activation by receptor‐bound urokinase: A kinetic study with both cell‐associated and isolated receptor
53. Dynamics of the multidomain fibrinolytic protein urokinase from two‐dimensional NMR
54. Conformation of one‐ and two‐chain high molecular weight urokinase analyzed by small‐angle neutron scattering and vacuum ultraviolet circular dichroism
55. Plasminogen receptors: Ubiquitous sites for cellular regulation of fibrinolysis
56. Plasminogen activation by receptor‐bound urokinase
57. 2‐macroglobulin
58. Macrophage fibrinolytic activity: Two pathways of plasmin formation by intact cells and an inhibitor of plasminogen activator
59. Inhibition of receptor‐bound urokinase by plasminogen‐activator inhibitors
60. Functional characteristics of receptor‐bound urokinase on human monocytes: Catalytic efficiency and susceptibility to inactivation by plasminogen activator inhibitors
61. The activation of pro‐urokinase by plasma kallikrein and its inactivation by thrombin
62. Human ovarian tumor‐associated trypsin. Its purification and characterization from mucinous cyst fluid and identification as an activator of pro‐urokinase
63. Activation of pro‐urokinase by the human T cell‐associated protease HuTSP‐1
64. Cathepsin B efficiently activates the soluble and tumor cell receptor‐bound form of the proenzyme urokinase‐type plasminogen activator (pro‐uPA)
65. In vivo paracrine interaction between urokinase and its receptor: Effect on tumor invasion
66. Localization of urokinase‐type plasminogen activator in stromal cells in adenocarcinomas of the colon in humans
67. Distribution of urokinase‐type plasminogen activator immunoreactivity in the mouse
68. Localization of urokinase‐type plasminogen activator messenger RNA in the normal mouse by in situ hybridization
69. Urokinase‐type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas
70. The plasminogen activation system in human colon cancer: Messenger RNA for the inhibitor PAI‐1 is located in endothelia cells in the stroma
71. Determination of the levels of urokinase and its receptor in human colon carcinoma cell lines
72. Localization of plasminogen activators in human colon cancer by immunoperoxidase staining
73. The plasmin system in human adenocarcinomas and their metastases
74. Growth factors in the regulation of pericellular proteolysis: A review
75. Urokinase receptor biosynthesis, messenger RNA level and gene transcription are increased by transforming growth factor‐beta1 in human A549 lung carcinoma cells
76. Localization of messenger RNA for 72‐kDa and 92‐kDa type IV collagenases in human skin cancers by in situ hybridization
77. A new member of the metalloproteinase gene family is specifically expressed in stromal but not in tumor cells of breast carcinomas
78. Plasminogen activator and mouse spermatozoa: Urokinase synthesis in the male genital tract and binding of the enzyme to the sperm cell surface
79. Urokinase receptors in human monocytes
80. Receptor mediated binding of the fibrinolytic components, plasminogen and urokinase, to peripheral blood cells
81. Sensitive and specific enzyme‐linked immunosorbent assay for urokinase‐type plasminogen activator and its application to plasma from patients with breast cancer
82. Phosphatidylinositol‐linked proteins and paroxysmal nocturnal hemoglobinuria
83. Paroxysmal nocturnal hemoglobmuria: Clinical manifestations, hematology, and nature of the disease
84. The major Fc receptor in blood has a phosphatidylinositol anchor and is deficient in paroxysmal nocturnal haemoglobinuria